Over at In the Pipeline, Derek Lowe wonders what compounds might make good metabolic disease targets, harkening back to one put out there in 2002 by a company called Sumitomo Pharmaceuticals. He sees promise in CAMKK2, in that it's more upstream and involved in numerous pathways for regulation of appetite and glucose levels, including ghrelin, AMPK, and NPY.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.